anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The procedure for the production of deep-frozen, portioned pulp food or mash food, which is designated for the consumption in the thermal condition, comprises heating a carrier raw material in a water bath by stream or with hot air at a core temperature (T1) of 75[deg] C, suddenly cooling the raw material at a lower temperature (T2) of 5[deg] C, mechanically mincing the raw material by a micro-cutter, mixing the minced raw material with protein and transferring the pulp- or mash mixture in a dimensionally stable pulp- or mash food through heating at a core temperature (T3) of 70[deg] C. The procedure for the production of deep-frozen, portioned pulp food or mash food, which is designated for the consumption in the thermal condition, comprises heating a carrier raw material in a water bath by stream or with hot air at a core temperature (T1) of 75[deg] C, suddenly cooling the raw material at a lower temperature (T2) of 5[deg] C, mechanically mincing the raw material by a micro-cutter, mixing the minced raw material with protein, transferring the pulp- or mash mixture in a dimensionally stable pulp- or mash food through heating at a core temperature (T3) of 70[deg] C and suddenly cooling the dimensionally stable pulp- or mash food. The raw material for example vegetables, meat, fish, cereals or pasta is mixed with the other ingredients and is cooled, portioned and then cooked in further sequence. The heated and the cooled raw material is added before and/or when admitting the liquid such as water, base, cream, milk and/or oil. The ratio of the raw material and the liquid is 50:50. The average sliced product of the cooled and minced raw material is 0.3 mm. The minced raw material mixes with protein with or without extra liquid and is mixed to a homogeneous pulp- or mash mixture. The mixture containing the minced raw material and protein are admixed with further ingredients that consist of binding agent such as modified starch, gelling agent such as cattle gelatin with a bloom grade of 180-240, spices and/or saturation supplement such as cream cheese, powder, semolina, rice, rice flakes and/or curd. The admixing of the protein and the further ingredients takes place in an individual operation. A mixture of powdered chicken protein and lactalbumin in the ratio of 80:20 is used as protein. The pulp- or mash mixture is filled in a temperature-resistant silicon mold before the heating process. The heating of the pulp- or mash mixture filled in the silicon mold and the transfer of the mixture in the stable pulp- or mash food takes place by hot air, in which the humidity is injected. The sudden cooling of the pulp- or mash food takes place between 5-20 min after the heating process. The heating time (60%) during the transferring of the mixture is larger than the heating time (70%) during the heating of the raw material. An independent claim is included for a deep-frozen, portioned pulp food or mash food.
STUDY OBJECTIVES: To examine if comorbid anxiety and depression symptoms (psychological distress) moderate intervention effect in participants receiving digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) in a large-scale randomized controlled trial (RCT), compared to a patient education (PE) control condition. Further, we investigate if dCBT-I reduced levels of psychological distress for those with insomnia and comorbid psychological distress.
METHODS: 1721 participants with insomnia completed online assessments of sleep, fatigue and psychological distress, at baseline and at nine-week follow-up. Primary outcome was Insomnia Severity Index (ISI), and secondary outcomes included self-reported sleep (diary), cognition, fatigue, and psychological distress. Participants with psychological distress (HADS>16) were separated from participants without psychological distress. Linear mixed models in SPSS were conducted to test the effects of the intervention.
RESULTS: At nine-week follow-up we found no difference in effect of the intervention between those who had comorbid psychological distress vs. those without psychological distress in terms of insomnia severity (p = 0.552) and fatigue (p = 0.744). Both groups had large effect size improvements on insomnia severity (p < 0.001=), small to medium (Cohen d < 0.08) improvements on fatigue (p < 0.01=) and sleep efficiency (p < 0.001), and small improvement on other sleep diary measures, compared to their respective control group. The psychological distress group showed a small, but statistically significant decrease in psychological distress (d = 0.2, p < 0.05) with dCBT-I compared to PE.
CONCLUSION: dCBT-I is a viable treatment for Insomnia also for those who have comorbid psychological distress.
OBJECTIVE: The phase II STARLIGHT study was conducted to investigate the efficacy/safety of fezolinetant in Japanese women and identify the optimal dose for future evaluation.
METHOD: Participants were perimenopausal/postmenopausal women aged ≥40 to ≤65 years from 36 centers in Japan seeking treatment/relief for vasomotor symptoms (VMS) associated with menopause. After screening, participants were randomized 1:1:1, stratified by menopausal status, to receive fezolinetant 15 or 30 mg or placebo orally once daily for 12 weeks. Participants completed a daily VMS diary. The primary endpoint was mean change in frequency of VMS of any severity from baseline to week 8. Secondary endpoints included mean change in VMS frequency from baseline each week up to week 12 and frequency/severity of adverse events.
RESULTS: A total of 147 participants were randomized (placebo, n = 47; fezolinetant 15 mg, n = 53; fezolinetant 30 mg, n = 47). Fezolinetant 15 and 30 mg demonstrated statistically significant reductions in mean VMS frequency at week 8 versus placebo. Least-squares mean estimates of mean change in frequency of VMS from baseline to week 8 were -7.04 for fezolinetant 15mg, -6.31 for fezolinetant 30mg, and -4.55 for placebo. The difference in least-squares mean estimates was -2.50 (95% CI: -4.03, -0.96), p = 0.002 for fezolinetant 15mg and placebo, and was -1.76 (95% confidence interval [CI]: -3.35, -0.17), p = 0.030 for fezolinetant 30mg and placebo. Reductions from baseline in mean VMS frequency versus placebo were seen after week 1 of treatment, maintained throughout 12 weeks. Fezolinetant was well tolerated, with no safety signals of concern for either dose to week 12.
CONCLUSION: Oral fezolinetant at once-daily doses of 15 or 30 mg was efficacious and well tolerated for treatment of mild, moderate and severe VMS associated with menopause in this Japanese study.
No application will be made to patients in this group for 12 weeks. Pre-test and post-test will be applied.
At the 12 week visit, participants randomized to the delayed diagnosis will complete the trial outcome assessments. After completing the 12 week final trial assessments they will be seen by the study respirologist and treated for their newly diagnosed asthma or COPD.
Uterine fibroids are the most common pelvic neoplasms in women; they severely impact quality of life and are the leading indication for hysterectomy. Hysterectomy is the definitive treatment for myomas; however, many patients seek alternative uterine-sparing therapy and desire to conserve their fertility. Myomectomy is a much-reported surgical option for women with symptomatic fibroids and, until recently, the abdominal approach has been the approach of choice for most surgeons. Over time, patients have requested less invasive procedures and minimally invasive, laparoscopic options are becoming more popular among patients and their gynecologists. Standard surgical and interventional treatments for uterine fibroids are costly to society and to the health care system. New technologies such as GFA may offer a low-cost alternative to the standard treatments for symptomatic uterine fibroids in women who desire uterine conservation. This study seeks to evaluate those cost differences between three available uterine-sparing techniques and to explore the qualitative outcomes such as symptom severity, health related quality of life, and overall treatment effect.
Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. (See CONTRAINDICATIONS.) 

Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution contains dorzolamide (which is a sulfonamide) and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. Patients should be advised that if serious or unusual reactions or signs of hypersensitivity occur, they should discontinue the use of the product (see WARNINGS). 

Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and lid reactions, they should discontinue use and seek their physician's advice. 

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. 

Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. (See PRECAUTIONS, General.) 

Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container. 

If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart. 

Patients should be advised that Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution.
OBJECTIVE: Virtual Reality (VR) has been demonstrated to be an effective option for integrating psychological interventions in different therapeutic settings. This randomized controlled interventional study aims to assess the effects of VR, compared to tablet controlled intervention, on anxiety, depression, pain, and short-term psychophysical symptoms in advanced cancer patients assisted at home.
METHODS: Participants were provided with a VR headset or a tablet (TAB) for 4 days. On the first and last day, anxiety and depression were measured by Hospital Anxiety and Depression Scale and pain by Brief Pain Inventory. Before and after each VR and tablet session, symptoms were collected by the Edmonton Symptom Assessment Scale (ESAS).
RESULTS: Fifty-three patients (27 VR vs. 26 TAB) completed the study. Anxiety significantly decreased in the VR group after the 4-day intervention. The analysis of ESAS showed a significant improvement in pain (p = 0.013), tiredness (p < 0.001), and anxiety (p = 0.013) for TAB group, and a significant reduction in tiredness (p < 0.001) in the VR group.
CONCLUSIONS: Technological and user-friendly tools, such as VR and tablets, might be integrated with traditional psychological interventions to improve anxiety and cancer-related short-term symptoms. Further studies are needed to better consolidate the possible beneficial effects of VR.
PURPOSE: An MRI contrast media and a method for manufacturing the same are provided to obtain MRI contrast media at high yield through simple process and to apply in electric-chemical catalyst and pharmaceutical field. CONSTITUTION: A magnetic resonance image contrast media of paramagnetic dinickel mycrocyclic complex is denoted by chemical formula 3. In chemical formula 3, R is alkyl, hydroxyl, or nitrile and Y is monovalent anion. A method for manufacturing the contrast media comprises: a step of reacting the nickel(II) complex compound of chemical formula 1 with oxalic acid in a ratio of 2:1 to obtain a compound of chemical formula 3; a step of reacting the oxalate with the nickel(II) complex compound of chemical formula 2; and a step of adding NaClO4, NH4PF6, NaBF4, or LiCF3SO3 to obtain a compound of chemical formula 3. The first reaction is performed at 50°C-100°C for 30-50 minutes. The second reaction is performed at 50°C-100°C for 10-40 minutes.
A system for providing remote direction of a user of ultrasound equipment comprising a local apparatus comprising an ultrasound tool 14 and an augmented reality device 16 for capturing video 26, displaying an ultrasound image, and displaying directions to the user 38, fig 3, and a remote apparatus 28 for displaying the captured video and generating directions using a controller 30 wherein the remote apparatus provides the direction data to the augmented reality device. The ultrasound tool may be an ultrasound transducer and the augmented reality device may be a headset. The AR device may display a visual representation of the directional data and may further display a translucent rendering of the ultrasound transducer. The directional data may be rendered as path-lines or trajectory data representing a recommended path of travel. The controller may comprise trackable sensors or fiduciary markers. The system may utilise wireless internet protocol and may comprise portable computing devices such as a phone or tablet.
The present invention relates to a functional cosmetic composition comprising an exosome of Brassica oleracea var. italica as an active ingredient, and to functional cosmetics containing the same. The exosome of Brassica oleracea var. italica has a bilayer lipid membrane structure and is absorbed into a skin cell. The absorbed exosome removes active oxygen in the skin cell and stimulates various antioxidant signaling mechanisms, thereby exhibiting antioxidant effect and promoting the synthesis of collagen and hyaluronic acid. Therefore, exosomes of Brassica oleracea var. italic can be effectively used in manufacturing functional cosmetics for skin aging prevention, skin whitening, wrinkle improvement and skin cell regeneration.
Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
ANKASCIN 568-P is a fermented product from the red yeast rice fungus \<Monascus purpureus NTU 568\>. It does not contain Monacolin K, an ingredient that may harm the human body, and is rich in new active ingredients. Take 2 red yeast rice capsules (each containing 440mg ANKASCIN 568-P) every day, and the control group takes 2 placebo capsules (containing equal weight maltodextrin) every day, respectively, at the 0th, 4th , , 12, 24, Collect blood samples for biochemical analysis and record the general body position measurement, blood pressure, blood lipid, blood sugar and other related changes of the subjects, and monitor the liver, kidney, and thyroid functions.
Phosphodiesterase-4 (PDE4), an important member of the PDE superfamily, is a key regulator of intracellular cyclic AMP (cAMP) level. As the second messenger, cAMP activates protein kinase A, which phosphorylates the subsequent downstream cAMP-response element binding (CREB) protein. In the central nervous system, this signaling cascade exerts both pre- and post-synaptic effects and is essential for a variety of cellular functions, including neurotransmitter release and neuroprotection. Inhibition of PDE4 prevents cAMP breakdown, which is well recognized as the mechanism by which PDE4 inhibitors can treat impaired memory linked to several brain disorders. In pre-clinical studies and early-stage clinical trials, PDE4 inhibitors such as rolipram have been shown to enhance memory. They also improve depressive-like behaviors induced by chronic unpredictable mild stress, lipopolysaccharide, or ethanol abstinence . Consequently, it is reasonable to believe that PDE4 is a potential target for treatment of the comorbidity of depression and AD.

The aim of the current study is to evaluate the potential adjunct antidepressant effect of Roflumilast in adult patients with MDD. Furthermore, we will assess the relationship between HAM-D score and BDNF as well as their role as a therapeutic targets of MDD.
The invention belongs to the technical field of health care, and particularly relates to a medicine pillow for preventing and treating influenza. The medicine pillow for preventing and treating influenza comprises a pillow body. A sandwich layer is arranged on the inner side of the pillow body, and is filled with liquid medicine. The liquid medicine comprises the following raw materials in part by weight: 25-40 parts of radix isatidis, 12-25 parts of selfheal, 5-11 parts of wild chrysanthemum, 6-8 parts of folium mori, 4-13 parts of honeysuckle, 7-14 parts of agastache rugosus and 4-6 parts of mint. The sandwich layer is provided with an electric heating wire; and a temperature-control switch is arranged on the outer side of the pillow body. The liquid medicine in the medicine pillow has a gentle medicine property, does not have side effects, does not contain antibiotics or hormone, is not harmful to human bodies, and can treat the influenza of a patient suffering from the influenza when the patient falls asleep; the patient can recover from the influenza easily; and the influenza of the patient can be treated radically after the patient uses the medicine pillow for a long time.
The intervention group will receive a total of 43 text messages. Text messages were developed using the Behavior Chang Wheel (BCW) through a systematic process linked to specific behavior change techniques. The text messages will provide practical information or guidance to influence selection and eating healthy diet for type 2 diabetes care. The text messages were either loss- or gain-framed to increase influence on behavioral decisions. Additionally, the participants will receive a text message to rate their ability on selection of food and eating of healthy diet based on the messages received in the month. The combination of the one-way and two-way messages in this group are designed to increase engagement of the participants.
BACKGROUND: The mortality rate of COVID-19 patients with critical symptoms is reported to be 40.5%. Early identification of patients with poor progression in the critical cohort is essential to timely clinical intervention and reduction of mortality. Although older age, chronic diseases, have been recognized as risk factors for COVID-19 mortality, we still lack an accurate prediction method for every patient. This study aimed to delve into the cell-free DNA fragmentomics of critically ill patients, and develop new promising biomarkers for identifying the patients with high mortality risk.
METHODS: We utilized whole genome sequencing on the plasma cell-free DNA (cfDNA) from 33 COVID-19 patients with critical symptoms, whose outcomes were classified as survival (n = 16) and death (n = 17). Mitochondrial DNA (mtDNA) abundance and fragmentomic properties of cfDNA, including size profiles, ends motif and promoter coverages were interrogated and compared between survival and death groups.
RESULTS: Significantly decreased abundance (~ 76% reduction) and dramatically shorter fragment size of cell-free mtDNA were observed in deceased patients. Likewise, the deceased patients exhibited distinct end-motif patterns of cfDNA with an enhanced preference for "CC" started motifs, which are related to the activity of nuclease DNASE1L3. Several dysregulated genes involved in the COVID-19 progression-related pathways were further inferred from promoter coverages. These informative cfDNA features enabled a high PPV of 83.3% in predicting deceased patients in the critical cohort.
CONCLUSION: The dysregulated biological processes observed in COVID-19 patients with fatal outcomes may contribute to abnormal release and modifications of plasma cfDNA. Our findings provided the feasibility of plasma cfDNA as a promising biomarker in the prognosis prediction in critically ill COVID-19 patients in clinical practice.
Mesna may be given on a fractionated dosing schedule of a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below.

Mesna injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. MESNEX tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of mesna is 100% of the ifosfamide dose. The recommended dosing schedule is outlined in Table 2.

The efficacy and safety of this ratio of intravenous mesna and oral MESNEX has not been established as being effective for daily doses of ifosfamide higher than 2 g/m2. 

Patients who vomit within two hours of taking oral MESNEX should repeat the dose or receive intravenous mesna.
PROBLEM TO BE SOLVED: To obtain a new antitumor compound causing degeneration in tumor cells and synthesized by Serratia marcescens from substances originated in the tumor cells. SOLUTION: This compound is synthesized by Serratia marcescens from substances originated in tumor cells. The compound of the formula is obtained by decomposing a substance originated in the tumor cells (base material for synthesis of antitumor substance = tumor cell-degenerating substance) by Serratia marcescens. The above mentioned substance originated in the tumor cells is obtained e.g. by following steps; a tumor cell culture ascites obtained by using a DDY mouse and Ehrlich tumor cells is heat-treated and extracted with ethanol, acetone, chloroform and the like by turns and the resultant concentrate is separated with paper chromatography [descent method; developing liquid is a mixed liquid composed of (butanol/glacial acetic acid/water)=(4:1:2)] to extract a ninhydrine reaction-positive substance having Rf=0.25-0.3.  By using a culture solution including the substance originated in tumor cells and cultivating the Serratia marcescens, the compound of the formula is obtained from the preparation.
BACKGROUND: Infection is the cause of diarrhoea, and rotaviruses and adenoviruses are important pathogens in children.
METHODS: A retrospective study was conducted on 144,067 children with diarrhoea between 2014 and 2023 in China. We used the colloidal gold method to detect intestinal adenovirus and rotavirus A antigens in faeces. The epidemiological characteristics of these viruses and the impact of meteorological factors on them were analysed before and after coronavirus disease 2019 (COVID-19) pandemic.
RESULTS: During this decade, the positive rate of adenovirus infection was 6.41%, while the positive rate of rotavirus A infection was 11.81%, higher than that of adenovirus infection. The positive rate of adenovirus and rotavirus A coinfection was 1.92%. The positive rates of adenovirus, rotavirus A and coinfection showed a fluctuating trend, and suddenly decreased in 2020. There was an apparent decrease of positive rate of rotavirus A, with a decrease of 57.27%, during 2020-2023. Surprisingly, the positive rate of adenovirus infection exceeded that of rotavirus A infection in 2021 and 2023. During the COVID-19 pandemic, the proportion of female patients and children over two years of age infected with adenovirus or rotavirus A increased, while the proportion of cases in winter decreased. In addition, we found that the positive rate of rotavirus A infection was related to average temperature and sunshine, and the positive rate of adenovirus and rotavirus A coinfection was only related to sunshine. However, these correlations disappeared during the COVID-19 pandemic.
CONCLUSIONS: This study revealed the recent prevalence of adenovirus and rotavirus A infections in children with diarrhoea in south-central China and provided a theoretical basis for the prevention and control of viral diarrhoea.